Oppenheimer Issues Pessimistic Forecast for Bicycle Therapeutics (NASDAQ:BCYC) Stock Price

Bicycle Therapeutics (NASDAQ:BCYC) had its price target reduced by stock analysts at Oppenheimer from $44.00 to $36.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

BCYC has been the topic of several other research reports. Citizens Jmp lowered their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Morgan Stanley reissued a “sell” rating and issued a $13.00 target price on shares of Bicycle Therapeutics in a research report on Tuesday. Truist Financial set a $8.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. Needham & Company LLC dropped their price objective on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Royal Bank Of Canada cut their price objective on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $14.50.

Bicycle Therapeutics Stock Down 3.2%

Shares of NASDAQ:BCYC opened at $4.55 on Wednesday. Bicycle Therapeutics has a 12-month low of $4.47 and a 12-month high of $9.86. The business has a 50 day moving average of $5.83 and a 200-day moving average of $6.78. The stock has a market cap of $315.63 million, a PE ratio of -1.44 and a beta of 1.65.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.71. The company had revenue of $47.96 million for the quarter, compared to analyst estimates of $7.08 million. Bicycle Therapeutics had a negative return on equity of 33.21% and a negative net margin of 301.66%. Equities research analysts expect that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Kevin Lee sold 10,989 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the sale, the chief executive officer directly owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the transaction, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. The trade was a 4.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 38,029 shares of company stock valued at $251,966. Corporate insiders own 22.90% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Flax Pond Capital LLC bought a new stake in shares of Bicycle Therapeutics during the 4th quarter worth approximately $1,229,000. Invesco Ltd. bought a new position in Bicycle Therapeutics in the fourth quarter valued at approximately $71,000. State of Tennessee Department of Treasury increased its stake in Bicycle Therapeutics by 36.4% in the fourth quarter. State of Tennessee Department of Treasury now owns 61,153 shares of the company’s stock valued at $433,000 after acquiring an additional 16,311 shares during the last quarter. XTX Topco Ltd raised its position in Bicycle Therapeutics by 309.3% during the fourth quarter. XTX Topco Ltd now owns 47,674 shares of the company’s stock valued at $338,000 after purchasing an additional 36,026 shares in the last quarter. Finally, Virtus Investment Advisers LLC raised its position in Bicycle Therapeutics by 172.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 35,709 shares of the company’s stock valued at $253,000 after purchasing an additional 22,615 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Bicycle Therapeutics

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Oppenheimer cut its price target from $44 to $36 but maintained an “outperform” rating—still implying large upside from current levels. Read More.
• Positive Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating, signaling continued analyst conviction despite the reduction. Read More.
• Positive Sentiment: Citizens JMP trimmed its target from $12 to $8 and kept a “market outperform” view, which supports a constructive medium‑term outlook. Read More.
• Neutral Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and set a “sector perform” rating—more neutral guidance relative to prior coverage. Read More.
• Negative Sentiment: Multiple short‑interest notices flagged a “large increase” in short interest for March, although the published figures show zero shares (likely a data/reporting inconsistency). Still, headlines alone can prompt selling or caution among investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.